Enhancing survival and quality of life for people living with GIST through patient-powered research, education and empowerment, and global advocacy efforts.
These are our Core Values:
Patient-reported Treatment Responses in Known/Likely SDH-deficient GISTS: An Analysis of The Life Raft Group Observational Registry. This study highlights the very unique research role that defines The Life Raft Group.
The INTRIGUE study is a Phase 3 clinical trial testing the investigational drug ripretinib (DCC-2618) for patients living with GIST that are no longer on imatinib due to progression or intolerance.